AG
VKTX icon

Aperio Group’s Viking Therapeutics VKTX Stock Holding History

Aperio Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$150K Buy
26,697
+14,717
+123% +$89.1K ﹤0.01% 2351
2020
Q3 		$70K Buy
+11,980
New +$82.5K ﹤0.01% 2342
2019
Q3 		– Sell
-1,248
Closed -$10K – 2750
2019
Q2 		$10K Buy
+1,248
New +$10.7K ﹤0.01% 2787

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aperio Group's VKTX Position: Q4 2020 in Review

Aperio Group increased its Viking Therapeutics (VKTX) stake by 123% in Q4 2020, buying an estimated $89.1K and bringing the position to 26,697 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

Aperio Group first reported a position in VKTX in Q2 2019 and has held it in 3 quarters since. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

  • Aperio Group held 26,697 shares of Viking Therapeutics worth $150K as of Q4 2020.
  • Aperio Group bought 14,717 Viking Therapeutics shares in Q4 2020, an estimated $89.1K.
  • Viking Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2351 holding.
  • Aperio Group first reported a position in Viking Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.